Shanghai Allist Pharmaceuticals (688578) Q4 2025 earnings summary

Executive summary

• Achieved revenue of ¥5.19 billion in 2025, up 45.8% year-over-year, driven by core oncology products.

• Net profit attributable to shareholders reached ¥2.19 billion, up 53.1% year-over-year.

• Core product Furmonertinib (伏美替尼) continued strong sales; Glecirasib (戈来雷塞) launched and contributed to revenue.

• All major product indications included in national medical insurance, expanding patient access.

• Board proposes a cash dividend of ¥450 million for 2025, representing 20.56% of net profit.

Financial highlights

• Revenue: ¥5.19 billion, up 45.8% year-over-year.

• Net profit attributable to shareholders: ¥2.19 billion, up 53.1% year-over-year.

• Operating cash flow: ¥2.32 billion, up 48.3% year-over-year.

• Gross margin for oncology products: 97.28%.

• Basic and diluted EPS: ¥4.86, up 53.1% year-over-year.

• R&D investment: ¥539.7 million, 10.4% of revenue.

Outlook and guidance

• Plans to further expand clinical applications of Furmonertinib, including new indications and combination therapies.

• Continued investment in R&D to enrich the product pipeline and maintain innovation leadership.

• Focus on strengthening commercialization and market penetration for new and existing products.

• Ongoing talent development and digital transformation to support sustainable growth.